APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the presence of CML, however, co-treatment of CIGB-258 inhibited the glycation of apoA-I and protected the degradation of apoA-I, exerting enhanced ferric ion reduction ability.